Please login to the form below
Novartis' patupilone fails phase III trial
Novartis has announced that its investigative compound, patupilone, has failed a phase III trial of patients with advanced ovarian cancer
Novartis has announced that its investigative compound, patupilone (EPO906), has failed a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy.
The compound was tested in a phase III study carried out in around 168 sites across 22 countries. The randomised study, which involved 829 patients with epithelial ovarian, primary fallopian or primary peritoneal cancer, compared patupilone with Doxil/Caelyx (pegylated liposomal doxorubicin).
The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, safety and overall response rate. Patupilone did not show a significant overall survival advantage. Based on this, Novartis does not plan to proceed with regulatory filings based on these data.
Share
Related Hub content
Featured jobs
-
Medical Writers
-
Competitive Salary and Benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
-
Associate Medical Director
-
Highly Competitive
-
Account Manager / Account Director
-
Competative
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- Global Surgical Microscope Market Growth Report Till 2023
- Rosuvastatin Calcium Market Current and Future Industry Trends, 2018 – 2023
- Pediatric Physiotherapy Market providing information on Key Players, Growth Drivers and Industry challenges
- Dental Implants Market Current and Future Industry Trends, 2018 – 2023
- Contraceptives Oral Solids Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2023
- FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
